Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.98 | — | — | — | — | — | — | — | — | — | — | — | — | 2.67 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.07 | — | — | — | 3.03 | 6.20 | 9.78 | 3.14 | 3.27 | 10.35 | 7.69 | 11.58 | 38.89 | 8.94 | 1.25 | 7.36 | 7.71 | 8.72 | 9.48 | 15.91 | — |
| — | — | — | — | -7.1% | -40.1% | +27.2% | -72.9% | -91.6% | +15.8% | +513.4% | +57.5% | +404.3% | +2.5% | -86.8% | -53.8% | — | — | — | — | — | |
| P/B Ratio | 0.81 | 2.33 | 1.82 | 1.36 | 0.81 | 2.04 | 0.94 | 1.53 | 3.38 | 4.99 | 3.25 | 3.48 | 2.40 | 1.43 | 0.39 | 1.14 | 1.36 | 0.98 | 1.02 | 1.80 | 2.69 |
| — | +14.7% | +93.1% | -11.0% | -75.9% | -59.2% | -71.0% | -56.2% | +40.8% | +248.3% | +734.5% | +205.7% | +75.8% | +45.6% | -62.0% | -36.6% | -49.2% | -73.1% | -41.3% | -30.3% | +16.9% | |
| P/FCF | — | — | — | — | — | — | — | — | 5.25 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | -90.3% | -385.0% | -798.1% | -125.9% | -80.2% | -99.7% | -107.0% | -147.7% | -693.8% | -211.8% | -173.5% | -187.5% | -259.3% | -269.9% | 13.5% | 33.9% | — |
| — | — | — | — | -12.5% | -286.0% | -646.0% | +14.8% | +88.4% | +52.9% | +38.4% | +21.2% | -167.5% | +21.5% | -1386.3% | -652.2% | — | — | — | — | — | |
| Operating Margin | — | — | — | — | -173.3% | -494.8% | -1320.1% | -171.5% | -124.6% | -197.4% | -204.9% | -278.1% | -1242.2% | -542.1% | -349.1% | -400.3% | -582.9% | -666.5% | -1015.7% | -786.4% | — |
| — | — | — | — | -39.1% | -150.7% | -544.3% | +38.3% | +90.0% | +63.6% | +41.3% | +30.5% | -113.1% | +18.7% | +65.6% | +49.1% | — | — | — | — | — | |
| Net Margin | — | — | — | — | -162.1% | -466.3% | -1273.6% | -170.4% | -119.8% | -187.5% | -192.3% | -265.3% | -1157.6% | 329.9% | -402.4% | -508.0% | -692.3% | -1169.4% | -1027.7% | -786.3% | — |
| — | — | — | — | -35.3% | -148.6% | -562.2% | +35.8% | +89.6% | -156.8% | +52.2% | +47.8% | -67.2% | +128.2% | +60.8% | +35.4% | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.8% | -14.1% | -20.8% | -9.7% | -13.8% | -32.1% | -26.9% | -29.5% | -26.9% | -20.4% | -18.5% | -18.2% | -16.7% | 14.4% | -28.0% | -18.3% | -27.3% | -29.0% | -24.9% | -20.3% | -21.5% |
| — | +56.2% | +22.8% | +67.2% | +48.6% | -57.5% | -45.3% | -61.9% | -61.3% | -241.7% | +33.8% | +0.3% | +39.0% | +149.6% | -12.5% | +9.9% | -27.0% | -80.5% | -41.4% | +30.9% | +5.0% | |
| ROA | -59.2% | -11.4% | -17.4% | -8.3% | -11.0% | -25.3% | -22.8% | -23.3% | -20.4% | -17.0% | -15.3% | -15.3% | -14.4% | 10.1% | -15.9% | -10.2% | -14.8% | -17.2% | -16.1% | -13.9% | -16.3% |
| — | +54.9% | +23.6% | +64.2% | +46.4% | -48.6% | -48.7% | -52.2% | -42.0% | -268.8% | +3.8% | -50.0% | +2.8% | +158.5% | +1.1% | +26.8% | +9.2% | -33.4% | -22.9% | +22.8% | -7.4% | |
| ROIC | -20410.9% | — | — | -185.0% | -387.4% | -772.8% | -4199.1% | — | -1022.1% | -146.3% | — | — | -3290.6% | -34.6% | -19.9% | -16.5% | -33.6% | -24.3% | -45.5% | -50.3% | -44.6% |
| — | — | — | — | +62.1% | -428.4% | — | — | +68.9% | -322.5% | — | — | -9691.2% | -42.6% | +56.2% | +67.3% | +24.6% | +43.1% | -32.7% | -34.6% | -11.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.47 | 0.39 | 0.34 | 0.41 | 0.33 | 0.27 | 0.23 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +43.4% | +44.0% | +48.6% | +115.1% | +95.2% | -39.8% | -42.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.39 | 6.03 | 4.79 | 8.39 | 6.50 | 3.45 | 6.79 | 6.36 | 3.15 | 5.92 | 6.12 | 5.57 | 7.01 | 7.52 | 2.10 | 2.14 | 1.99 | 2.17 | 3.78 | 3.56 | 6.25 |
| — | +74.6% | -29.5% | +31.9% | +106.1% | -41.7% | +11.1% | +14.1% | -55.0% | -21.2% | +191.7% | +160.8% | +252.9% | +245.9% | -44.5% | -40.1% | -68.2% | -79.5% | -76.8% | -6.5% | +24.1% | |
| Quick Ratio | 8.39 | 6.03 | 4.79 | 8.39 | 6.50 | 3.45 | 6.79 | 6.36 | 3.15 | 6.62 | 6.12 | 5.57 | 7.01 | 7.52 | 2.10 | 2.14 | 1.99 | 2.17 | 3.78 | 3.56 | 6.25 |
| — | +74.6% | -29.5% | +31.9% | +106.1% | -47.9% | +11.1% | +14.1% | -55.0% | -11.9% | +191.7% | +160.8% | +252.9% | +245.9% | -44.5% | -40.1% | -68.2% | -79.5% | -76.8% | -6.5% | +24.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MRKR stock.
Marker Therapeutics, Inc.'s current P/E is -2.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Marker Therapeutics, Inc.'s business trajectory between earnings reports.